Uncover Mechanism, Diversify Design, Expand Indication

Enhance VEGFxPD1 Mechanistic Understanding, Target Selectivity & Binding Affinity to Supercharge the Discovery & Development of Bispecifics in Oncology & Autoimmune Diseases

Groundbreaking data from Akeso and Summit Therapeutics has shown that ivonescimab reduced the risk of disease progression by 49% compared to Keytruda in NSCLC, redefining the strategic landscape for bispecific development. As a result, bispecifics continue to deliver real-world clinical success, from PD-1xVEGF to CD3-based TCEs. However, drug developers now face new challenges in translating this progress into best-in-class therapies.

While bispecific developers work to understand the mechanistic basis of this target combination, the industry strives to find the next best target. As development diversifies beyond oncology into autoimmune diseases and T-Cell Engagers, 2025 stands as a pivotal year to shape current and future bispecific development.

The 16th World Bispecific Summit returns as the industry’s longest-running and most comprehensive event, devoted exclusively to the design, development, and translation of bispecific and multispecific therapeutics. Bringing together the industry leaders, making it all happen, including Regeneron, Sanofi, Novartis, Immunocore, Zymeworks, and more to share actionable insights and real-world case studies. Attendees will gain strategies to design more effective bispecifics, select smarter target pairings, streamline manufacturability, and mitigate safety risks - accelerating the path from discovery to clinic.

All of the speakers were excellent. Their professional knowledge and experiences will be a great help in the development of our pipelines.

SG Medical

Great opportunity to meet and network with leading scientists and industry experts in the field of bispecific antibodies.

Boehringer Ingelheim

Engaging science and a variety of strong presentations and discussions highlighting innovative approaches that are being implemented and tested in the rapidly developing field of bispecifics.

Eli Lilly

Explore the Full Event Guide

  • 25+ World-Class Speakers
  • Days of Exclusive Insights into Bispecific & Multispecific Antibody Drug Development
  • Exclusive Networking & Partnering Opportunities
  • Focused Industry-Led Community of Top Bispecific & Multispecific Biopharma
AgBio Tech (5)

What To Expect

100+

Attendees from Biopharma & Academia

25+

World-Class Speakers

8+

C-Level
Speakers

3+

Hours of In-Person Networking

1

Pre-Conference Focus Day

1

Panel Discussion

Official Partners

Lead Partner

Program Partner

Exhibition Partners

Innovation Partners

Screenshot-2025-04-28-103240
Explore the Agenda

Uncover the latest advances in bispecific development, from novel PD-1/VEGF breakthroughs to emerging autoimmune applications. Gain exclusive insights into target selection, translational hurdles, and clinical strategy through expert-led panels and interactive roundtable discussions.

IPFsummit-213
Partner With Us

Align your brand with industry leaders driving the future of Bispecifics. Showcase your expertise and connect with senior decision-makers actively seeking innovative discovery, development, and manufacturing solutions.

IPF-summit-networking
Join Biopharma Experts

Engage in high-impact discussions with peers across discovery, preclinical, translational, and clinical development. Build meaningful relationships and explore strategic opportunities through structured and informal networking sessions.